3 active not recruiting, 2 completed, 1 recruiting. 4 Phase 1, 3 Phase 2.
By phase and status
Follow AZD9550: new trials by email Literature Review of AZD9550 trials Research Report on AZD9550
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
AZD6234, AZD9550 - Hepatic Impairment | Phase 1 | Recruiting | AstraZeneca | 28 | 2026-03-20 | 2026-10-22 |
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP) - Healthy Participants | Phase 1 | Active not recruiting | AstraZeneca | 100 | 2025-06-04 | 2026-10-13 |
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
AZD6234, Placebo, AZD9550 - Obesity/Overweight | Phase 2 | Active not recruiting | AstraZeneca | 16 | 2025-05-20 | 2026-09-29 |
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
AZD9550, AZD6234, Placebo comparator - Obesity or Overweight | Phase 2 | Completed | AstraZeneca | 377 | 2025-02-18 | 2026-06-03 |
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
AZD9550, placebo, AZD9550 and AZD6234 - Overweight and Obesity | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 166 | 2023-09-29 | 2026-08-26 |
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
AZD9550, Placebo - Non-alcoholic Steatohepatitis | Phase 1 | Completed | AstraZeneca | 48 | 2023-05-02 | 2023-12-11 |
Conditions studied
Obesity (4) · Overweight (4) · Non-alcoholic Fatty Liver Disease (2) · Diabetes Mellitus, Type 2 (1) · Fatty Liver (1) · Liver Diseases (1) · Lymphoma, Follicular (1) · Weight Loss (1)
Sponsors
AstraZeneca (6)
Countries
United States (3) · Canada (2) · Germany (2) · Japan (2) · Australia (1) · Austria (1) · China (1) · Sweden (1) · United Kingdom (1)
NIH funding
2023 (1)